The aim of the NEMO study is to develop an effective antiepileptic drug regimen suitable for treatment of seizures in newborn babies using innovative strategies targeted specifically to the needs and peculiarities of babies.

In the first instance, NEMO study will evaluate bumetanide, a drug targeted at an age dependent mechanism which is thought to be responsible for the high incidence of seizure in the neonatal period. This will be the first time that an antiepileptic drug (AED) specifically aimed at this age-group will be evaluated in a large, adequately powered, randomised trial with EEG monitoring, recognised to be the “gold standard” method for seizure diagnosis in the newborn. Bumetanide cannot be tested as an AED on older children or adults as this mechanism ceases to be effective during the first few months of life.

More information about NEMO

To learn more about NEMO please please visit the NEMO website.


Unable to load Tweets

Stay in touch with the Neonatal Brain Consortium Ireland by signing up to
our newsletter

  • This field is for validation purposes and should be left unchanged.